GlaxoSmithKline Non Current Assets Total from 2010 to 2024

GSK Stock  USD 43.13  0.14  0.33%   
GlaxoSmithKline PLC Non Current Assets Total yearly trend continues to be quite stable with very little volatility. The value of Non Current Assets Total are projected to decrease to about 20.9 B. Non Current Assets Total is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. View All Fundamentals
 
Non Current Assets Total  
First Reported
1986-06-30
Previous Quarter
39.6 B
Current Value
40.4 B
Quarterly Volatility
17.3 B
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check GlaxoSmithKline PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlaxoSmithKline main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 B, Interest Expense of 502.2 M or Total Revenue of 19.9 B, as well as many exotic indicators such as Short Term Coverage Ratios of 2.26, Price Earnings Ratio of 13.46 or Price To Sales Ratio of 3.14. GlaxoSmithKline financial statements analysis is a perfect complement when working with GlaxoSmithKline PLC Valuation or Volatility modules.
  
This module can also supplement GlaxoSmithKline PLC's financial leverage analysis and stock options assessment as well as various GlaxoSmithKline PLC Technical models . Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.

Latest GlaxoSmithKline PLC's Non Current Assets Total Growth Pattern

Below is the plot of the Non Current Assets Total of GlaxoSmithKline PLC ADR over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. GlaxoSmithKline PLC's Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GlaxoSmithKline PLC's overall financial position and show how it may be relating to other accounts over time.
Non Current Assets Total10 Years Trend
Slightly volatile
   Non Current Assets Total   
       Timeline  

GlaxoSmithKline Non Current Assets Total Regression Statistics

Arithmetic Mean36,560,288,742
Geometric Mean28,077,859,073
Coefficient Of Variation44.69
Mean Deviation12,313,520,177
Median39,377,000,000
Standard Deviation16,339,607,151
Sample Variance266982761.9T
Range59.8B
R-Value0.56
Mean Square Error196609120.1T
R-Squared0.32
Significance0.03
Slope2,054,472,564
Total Sum of Squares3737758666T

GlaxoSmithKline Non Current Assets Total History

202420.9 B
202340.4 B
202239.4 B
202160.4 B
202060.2 B
201960.2 B
201841.1 B

About GlaxoSmithKline PLC Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include GlaxoSmithKline PLC income statement, its balance sheet, and the statement of cash flows. GlaxoSmithKline PLC investors use historical funamental indicators, such as GlaxoSmithKline PLC's Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although GlaxoSmithKline PLC investors may use each financial statement separately, they are all related. The changes in GlaxoSmithKline PLC's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on GlaxoSmithKline PLC's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on GlaxoSmithKline PLC Financial Statements. Understanding these patterns can help to make the right decision on long term investment in GlaxoSmithKline PLC. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Non Current Assets Total40.4 B20.9 B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for GlaxoSmithKline Stock analysis

When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Transaction History
View history of all your transactions and understand their impact on performance
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Dividend Share
0.58
Earnings Share
3.02
Revenue Per Share
14.97
Quarterly Revenue Growth
0.092
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.